ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

ClinicalTrials.gov ID: NCT01023958

Public ClinicalTrials.gov record NCT01023958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy

Study identification

NCT ID
NCT01023958
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
50 participants

Conditions and interventions

Conditions

Interventions

  • BI 6727, IV infusion Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 18, 2009
Primary completion
Sep 18, 2011
Completion
Sep 18, 2011
Last update posted
Nov 21, 2017

2009 – 2011

United States locations

U.S. sites
19
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
1230.2.5 Boehringer Ingelheim Investigational Site Beverly Hills California
1230.2.10 Boehringer Ingelheim Investigational Site Los Angeles California
1230.2.34 Boehringer Ingelheim Investigational Site Miami Florida
1230.2.29 Boehringer Ingelheim Investigational Site Orlando Florida
1230.2.6 Boehringer Ingelheim Investigational Site Chicago Illinois
1230.2.17 Boehringer Ingelheim Investigational Site Joliet Illinois
1230.2.24 Boehringer Ingelheim Investigational Site Metairie Louisiana
1230.2.1 Boehringer Ingelheim Investigational Site Baltimore Maryland
1230.2.25 Boehringer Ingelheim Investigational Site Las Vegas Nevada
1230.2.36 Boehringer Ingelheim Investigational Site Las Vegas Nevada
1230.2.19 Boehringer Ingelheim Investigational Site Lebanon New Hampshire
1230.2.20 Boehringer Ingelheim Investigational Site New York New York
1230.2.23 Boehringer Ingelheim Investigational Site New York New York
1230.2.12 Boehringer Ingelheim Investigational Site Charlotte North Carolina
1230.2.4 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
1230.2.38 Boehringer Ingelheim Investigational Site Beaumont Texas
1230.2.41 Boehringer Ingelheim Investigational Site Tyler Texas
1230.2.43 Boehringer Ingelheim Investigational Site Webster Texas
1230.2.44 Boehringer Ingelheim Investigational Site Fairfax Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01023958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 21, 2017 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01023958 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →